4:45 PM - 5:00 PM (PDT), Monday, June 13, 2022
Arzeda, the Protein Design Company(tm), has developed a platform combining structure and machine learning approaches with high-throughput lab testing to rapidly engineer new protein and enzymes de novo. Areas of applications include reduction of immunogenicity and design of human scaffolds with higher activity and selectivity against clinical targets. We have demonstrated the applicability of our technology to therapeutic enzyme in a strategic collaboration with a large government agency currently at the preclinical stage and are looking to expand our portfolio with strategic partners
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Injectable Therapeutic Enzyme
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Executive Officer